Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Telemonitoring-Plattform „CUREETY TECHCARE“ im Vergleich zur Standardversorgung für mTBNC-Patienten, die eine Erstbehandlung einleiten (ALTERNATIVE)

24. September 2026 aktualisiert von: UNICANCER

Eine randomisierte Phase-III-Studie zum Vergleich der digitalen Telemonitoring-Plattform „CUREETY TECHCARE“ mit dem üblichen Pflegestandard bei Patientinnen mit dreifach negativem metastasiertem Brustkrebs, die eine systemische Erstlinienbehandlung einleiten

The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.

The main questions it aims to answer are:

  • Is patient quality of life improved by using the telemonitoring platform?
  • Are patients hospitalized less frequently when using the telemonitoring platform?
  • Is the patient overall survival improved by telemonitoring ?

Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.

Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

31

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Arras, Frankreich
        • Institut de Cancérologie des Hauts-de-France (ICHF)
      • Auxerre, Frankreich
        • Centre Hospitalier d'Auxerre
      • Avignon, Frankreich
        • Sainte Catherine - Institut du Cancer Avignon Provence
      • Bayeux, Frankreich
        • CH Aunay-Bayeux
      • Beauvais, Frankreich
        • Centre Hospitalier Simone Veil de Beauvais
      • Beuvry, Frankreich
        • ICHF - Centre Pierre Curie
      • Blois, Frankreich
        • Hôpital Simone Veil de Blois
      • Bordeaux, Frankreich
        • Polyclinique bordeaux nord
      • Bourg-en-Bresse, Frankreich
        • Centre Hospitalier Fleyriat
      • Caen, Frankreich
        • Centre de Cancérologie Privé de Caen Maurice Tubiana
      • Caen, Frankreich
        • Centre Francois Baclesse
      • Carcassonne, Frankreich
        • Centre hospitalier de Carcasonne
      • Chambray-lès-Tours, Frankreich
        • Recherche Oncologie Clinqiue 37 (ROC 37)
      • Cholet, Frankreich
        • CH de Cholet
      • Colmar, Frankreich
        • CH Colmar
      • Creil, Frankreich
        • Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
      • Dijon, Frankreich
        • Centre Georges François Leclerc
      • Dunkirk, Frankreich
        • Institut Andrée Dutreix
      • Fréjus, Frankreich
        • Centre Hospitalier Intercommunal de Fréjus Saint Raphael
      • Grenoble, Frankreich
        • Groupe Hospitalier Mutualiste de Grenoble
      • La Rochelle, Frankreich
        • Groupe Hospitalier de La Rochelle-Ré-Aunis
      • La Réunion, Frankreich
        • CHU de la réunion
      • La Réunion, Frankreich
        • Clinique Sainte Clotilde
      • La Tronche, Frankreich
        • CHU Grenoble Alpes
      • Le Coudray, Frankreich
        • Centre Hospitalier Louis Pasteur
      • Le Mans, Frankreich
        • Centre Hospitalier Le Mans
      • Le Puy-en-Velay, Frankreich
        • Centre Hospitalier Emile Roux
      • Lorient, Frankreich
        • GHBS Lorient
      • Lyon, Frankreich
        • Clinique de la Sauvegarde
      • Lyon, Frankreich
        • Centre Leon Berard
      • Lyon, Frankreich
        • Hôpital Privé Jean Mermoz
      • Marseille, Frankreich
        • Institut Paoli Calmettes
      • Mont-de-Marsan, Frankreich
        • CHI de Mont-de-Marsan et du Pays des Sources
      • Montpellier, Frankreich
        • Centre de Cancérologie du Grand Montpellier
      • Nantes, Frankreich
        • Hôpital Privé du Confluent
      • Neuilly-sur-Seine, Frankreich
        • Clinique Ambroise-Pare Hartmann
      • Neuilly-sur-Seine, Frankreich
        • Hôpital Américain de PARIS
      • Nîmes, Frankreich
        • CHU de Nimes
      • Orléans, Frankreich
        • CHR Orleans
      • Osny, Frankreich
        • CHP Sainte-Marie
      • Paris, Frankreich
        • Diaconesses Croix Saint-Simon Hospital Complex
      • Pau, Frankreich
        • Centre hospitalier de Pau
      • Plérin, Frankreich
        • CARIO - Hopital Privé des Cotes d'Armor
      • Poitiers, Frankreich
        • CHU de Poitiers
      • Reims, Frankreich
        • Institut Godinot
      • Rouen, Frankreich
        • Clinique Mathilde - Les Hôpitaux Privés Rouennais
      • Saint-Etienne, Frankreich
        • CHU de Saint-Etienne
      • Saint-Mandé, Frankreich
        • Hia Begin
      • Tours, Frankreich
        • CHU de Tours
      • Vandœuvre-lès-Nancy, Frankreich
        • Institut de Cancérologie de Lorraine
      • Épagny, Frankreich
        • CH Annecy Genevois

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
  • Patients ≥18 years of age.
  • Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
  • Life expectancy > 6 months as per investigator estimate.
  • Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
  • Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
  • Affiliated to the social security system or equivalent health insurance.
  • Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
  • Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion Criteria:

  • Participation in another clinical trial using telemonitoring.
  • Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
  • Patient deprived of their liberty or under protective custody or guardianship.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Standard-Pflegegruppe
Experimental: Telemonitoring group

Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare".

Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient).

The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to definitive Health-Related Quality of life score Deterioration
Zeitfenster: At baseline then every 3 months, up to 24 months

The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred.

The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life.

At baseline then every 3 months, up to 24 months
Hospitalization-free survival
Zeitfenster: From randomization to death from any cause, up to 24 months

Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive.

From randomization to death from any cause, up to 24 months
Overall survival
Zeitfenster: From randomization to death from any cause, up to 24 months after last inclusion

overall survival is the length of time from randomization during which patients enrolled in the study remain alive.

From randomization to death from any cause, up to 24 months after last inclusion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time-to-treatment failure
Zeitfenster: From randomization to treatment discontinuation, up to 24 months

Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation.

From randomization to treatment discontinuation, up to 24 months
Toxicity-free survival
Zeitfenster: From randomization until the first event, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first.

From randomization until the first event, up to 24 months
Time to clinical deterioration
Zeitfenster: From randomization, to the date of the first clinical deterioration, up to 24 months

-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead).

From randomization, to the date of the first clinical deterioration, up to 24 months
Number of treatment lines
Zeitfenster: Throughout study completion, up to 24 months

Number of successive treatment lines offered to the patient from randomization to the end of the study.

Throughout study completion, up to 24 months
Incidence of Adverse Events
Zeitfenster: Throughout study completion, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

Throughout study completion, up to 24 months
Quality of life questionnaire - Core 30 (QLQ-C30)
Zeitfenster: At baseline then every 3 weeks, up to 24 months

Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.

The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

At baseline then every 3 weeks, up to 24 months
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
Zeitfenster: At baseline then every 3 weeks, up to 24 months

This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30.

The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

At baseline then every 3 weeks, up to 24 months
Treatment compliance and extent of exposure
Zeitfenster: Throughout study completion, up to 24 months

The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions.

Throughout study completion, up to 24 months
Compliance with the use of Cureety digital telemonitoring
Zeitfenster: Throughout study completion, up to 24 months

Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires.

Throughout study completion, up to 24 months
Satisfaction with Cureety telemonitoring
Zeitfenster: 3 months after randomisation for the patients and 1 year after the site activation for medical team

Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool.

3 months after randomisation for the patients and 1 year after the site activation for medical team
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
Zeitfenster: 6 months after randomisation

The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent).

6 months after randomisation
Socio-economic impact of digital telemonitoring
Zeitfenster: Throughout study completion, up to 24 months after randomization

Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations

Throughout study completion, up to 24 months after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Jérôme MARTIN-BABAU, MD, Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
  • Hauptermittler: Florence JOLY, MD, François Baclesse Center, Caen
  • Hauptermittler: Frédéric FITENI, MD, University hospital of Nîmes

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. Juli 2024

Primärer Abschluss (Tatsächlich)

1. Dezember 2025

Studienabschluss (Tatsächlich)

12. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

10. Juli 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Juli 2024

Zuerst gepostet (Tatsächlich)

17. Juli 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

24. September 2026

Zuletzt verifiziert

1. August 2025

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • UC-BCG-2309
  • IDRCB NUMBER: 2023-A02477-38 (Andere Kennung: CPP Sud-Méditerranée III)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .